Merck & Co., Inc. $MRK Position Raised by Mn Services Vermogensbeheer B.V.

Key Points

• Mn Services Vermogensbeheer B.V. increased its Merck stake by 1.5% in the third quarter, bringing its holdings to 730,921 shares valued at approximately $106.2 million. Institutional investors collectively own 76.07% of Merck.
• Merck reported quarterly revenue of $16.61 billion, up 5.1% year over year, and exceeded analysts’ adjusted EPS expectations. The company also pays a quarterly dividend of $0.85, equal to a 2.4% annualized yield.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and a $151.32 average price target, but Merck faces risks from patent expirations, generic competition, and a European injunction affecting its subcutaneous Keytruda formulation.

Mn Services Vermogensbeheer B.V. lifted its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 730,921 shares of the company's stock after purchasing an additional 10,500 shares during the quarter. Merck & Co., Inc. comprises 0.8% of Mn Services Vermogensbeheer B.V.'s portfolio, making the stock its 28th biggest holding. Mn Services Vermogensbeheer B.V.'s holdings in Merck & Co., Inc. were worth $106,210,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of MRK. Susquehanna Fundamental Investments LLC acquired a new stake in Merck & Co., Inc. in the second quarter valued at $11,470,000. Russell Investments Group Ltd. grew its holdings in Merck & Co., Inc. by 2.0% in the second quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company's stock valued at $331,931,000 after purchasing an additional 51,393 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Merck & Co., Inc. by 7.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company's stock worth $794,577,000 after purchasing an additional 402,011 shares during the period. Talon Private Wealth LLC purchased a new stake in Merck & Co., Inc. during the 2nd quarter worth $995,000. Finally, Panagora Asset Management Inc. lifted its position in shares of Merck & Co., Inc. by 410.5% during the fourth quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company's stock worth $74,255,000 after purchasing an additional 567,249 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Down 0.2%

Shares of Merck & Co., Inc. stock opened at $142.45 on Friday. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The stock has a 50 day moving average price of $143.59 and a two-hundred day moving average price of $128.16. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $351.45 billion, a P/E ratio of 113.96, a PEG ratio of 6.42 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business's revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts expect that Merck & Co., Inc. will post 2.67 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is currently 272.00%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with a PD-1/PD-L1 inhibitor. The decision expands Merck’s oncology portfolio and could create another commercial opportunity beyond Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, although that program remains at a very early stage. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating while trimming its price target modestly to $177, implying substantial upside based on the referenced price. The call indicates continued confidence in Merck’s long-term earnings and pipeline prospects. Morgan Stanley Raises Merck Analyst View
• Positive Sentiment: Merck’s shareholder dividend was highlighted as part of its income appeal, which may support investor interest while the company navigates product-cycle and patent risks. Merck Dividend Payment
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $145 but retained a “neutral” rating, suggesting limited near-term upside and a cautious view of Merck’s growth outlook. Cantor Fitzgerald Merck Price Target
• Neutral Sentiment: Articles comparing Innoviva and Merck frame MRK as a large-cap pharmaceutical value candidate, but provide no new company-specific catalyst likely to materially change the stock’s valuation today. INVA vs. MRK: Which Stock Is the Better Value Option?
• Negative Sentiment: A Dutch court granted Halozyme an injunction blocking Merck’s subcutaneous Keytruda in eight European markets. The ruling could delay or restrict commercialization of a potentially more convenient Keytruda formulation and heightens litigation risk. Halozyme Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Industry analysis identifies Merck as particularly exposed to near-term generic competition as major products approach patent losses. That raises concerns about revenue durability and increases the importance of successful launches such as WELIREG. Pharma’s $500 Billion Patent Problem

Insider Buying and Selling

In other news, EVP David Williams sold 52,847 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. The trade was a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MRK. Scotiabank boosted their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a "sector outperform" rating in a report on Tuesday, September 29th. Guggenheim increased their price objective on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, September 8th. Wells Fargo & Company raised their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an "overweight" rating in a research note on Friday, September 4th. Sanford C. Bernstein boosted their price objective on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research note on Tuesday, August 4th. Finally, UBS Group increased their target price on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Seventeen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and a consensus price target of $151.32.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.